Introduction: Smoking is associated with a higher risk of mortality, especially in smokers with cardiovascular and respiratory diseases. Smoking cessation remains the most effective approach in reducing smoking-related illness risks at all ages. For elderly smokers, smoking cessation has been proved to prolong life expectancy and reduce the risk of stroke and ischemic heart disease. However, a wide selection of smoking cessation medications makes prescribing challenging, especially among elderly smokers. Inability to recommend the best treatment may reduce the smoking cessation success rate in the elderly. Therefore, this study compares the effectiveness of pharmacotherapy available and correlate the effect of ageing on the effectiveness, leading to the recommendation of the best medication for elderly smokers. Method: A systematic searching strategy was performed in three different databases by using predetermined search strings. Results: Overall, this systematic review revealed that varenicline showed the greatest smoking cessation rate among the elderly, followed by bupropion and NRT. Conclusion: It is suggested that varenicline offered the best medical aid for smoking cessation in the elderly.

Polyunsaturated fatty acids (PUFAs) intake may be beneficial in many aspects during the early phase of life. This scoping review aims to examine the beneficial outcomes and intakes of omega-3 and omega-6 PUFA among children. An electronic database search on academic journals published from 2017 to 2021 was conducted using Science Direct, PubMed, and Google Scholar. A total of 35 studies were identified and included in this scoping review. Majority of the findings found that PUFAs intake has a beneficial impact on the growth development, mental and cognitive health among children whether they are malnourished, sick or healthy individuals. Overall, this review may provide additional information on the benefits and recommended intake of supplementing PUFAs on children. More detailed research on this topic is needed to support these findings since it will contribute to the formation of the dietary intervention.

Survival benefit of patients with advanced cancer was reported with intravenous vitamin C administration. Nevertheless, a recent systematic review failed to support the clinically use of vitamin C in cancer patients due to the diversity of interventions and cancer type. This study aimed to provide a scoping review of vitamin C utilisation and its impact on cancer treatment from the perspective of in vitro studies. The review was conducted using predefined search terms in three scientific databases. 44 articles were retrieved with a total of 15 cancer types being studied from 2015 to 2020. The findings were classified into primary and secondary outcome. The primary outcome refers to chief consequences of vitamin C treatment, while the secondary outcome denotes the additional advantages generated as a result of the primary outcome, which occurs both in monotherapy and combination therapy. This review discussed the major mechanism of vitamin C as anti-cancer and its relation with the outcomes.